
Jan 7 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:
ARROWHEAD PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF REDEMPLO® (PLOZASIRAN) FOR FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) IN CHINA
ARROWHEAD PHARMACEUTICALS: NMPA APPROVAL TRIGGERS $10 MILLION MILESTONE PAYMENT TO BE PAID BY SANOFI TO ARROWHEAD SUBSIDIARY VISIRNA THERAPEUTICS